We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL (THRiL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01125176
Recruitment Status : Recruiting
First Posted : May 18, 2010
Last Update Posted : September 25, 2017
Information provided by (Responsible Party):
Weill Medical College of Cornell University

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : November 2018
  Estimated Study Completion Date : May 2019